María Sanchez-Ronco

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

Manuel Cobo, Dolores Isla, Bartomeu Massutí et al. · Journal of Clinical Oncology · 2007 · 442 citations · Full text

Medicine, Molecular Medicine, Oncology +10

Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

Miguel Tarón, Yukito Ichinose, Rafael Rosell et al. · Clinical Cancer Research · 2005 · 336 citations

Medicine, Oncology, Pharmacology +17

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Rafael Rosell, Miguel Angel Molina, Carlota Costa et al. · Clinical Cancer Research · 2011 · 300 citations · Full text

Medicine, Molecular Biology, Oncology +17

Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery

Rafael Rosell, Enriqueta Felip, Miquel Tarón et al. · Clinical Cancer Research · 2004 · 127 citations

Medicine, Molecular Genetics, Oncology +17